| |
Entity | Adrenocortical carcinoma |
Note | Data mining of gene expression revealed positive regulation of genes involved in DNA damage and cell cycle pathways in samples from adrenocortical carcinoma patients, including CDC7, their higher levels were associated with worse overall survival (Subramanian and Cohen, 2019). |
| |
| |
Entity | Bladder cancer |
Note | In order to identify candidate genes associated with cisplatin-resistant bladder cancer cells, sensitive and cisplatin-resistant cell lines were used for microarray analysis to determine the differential expression of significant genes in resistance. A total of 18 genes, including CDC7, were significantly upregulated in cisplatin-resistant cell lines (Kim et al., 2016). |
| |
| |
Entity | Breast Cancer |
Note | In breast cancer, high CDC7 expression had been reported (Bonte et al., 2008; Zografos et al., 2019), and associated with the development of aggressive disease, including ERBB2 (HER2) overexpression, triple-negative subtypes, accelerated cell cycle progression, disrupted tumor differentiation, genomic instability, increased NPI score, and reduced disease-free survival (Rodriguez-Acebes et al., 2010). Using tissue microarray of a cohort of 2197 highly characterized breast carcinomas, CDC7 expression was found in 1088 samples (57%), of which 228 samples exhibited moderate or strong expression. High CDC7 levels were also related to medullary histotype, high tumor grade, estrogen receptor-negative status, high Ki67 expression; overexpression of TP53 and CDKN2A; and amplification of HER2, MYC, MDM2, CCND1, and ESR1, unfavorable tumor phenotype, and poor prognosis (Choschzick et al., 2010). In triple negative breast cancer cellular models, the dual CDC7/CDK9 inhibitor (PHA-767491) synergizes with tyrosine kinase inhibitors to overcome resistance to EGFR -targeted therapy (McLaughlin et al., 2019): combined inhibition of EGFR and CDC7/CDK9 reduced cell proliferation accompanied by apoptosis induction, G2/M cell cycle arrest, and DNA replication inhibition. Due to the rarity of male breast cancer (MBC), serum protein alterations have not been extensively studied. Using two-dimensional gel electrophoresis (2-DE) and matrix-assisted laser desorption/ionization time mass spectrometry (MALDI-TOF MS), a panel of differentially expressed serum proteins were identified, which included the high CDC7 expression in MBC patients (Zografos et al., 2019). |
| |
| |
Entity | Clear cell renal cell carcinoma |
Note | Ghatalia et al. (Ghatalia et al., 2016) analyzed the gene expression of kinases paired samples from primary and metastatic tumor tissues and found that CDC7 is more expressed in metastatic tumors. Using the Cancer Genome Atlas (TCGA) data, the authors also observed an association between high CDC7 expression and reduced metastasis-free survival (Ghatalia et al., 2016). DISEASE |
| |
| |
Entity | Cervical intraepithelial neoplasia |
Note | Using microarray analysis, CDC7 was found among highly expressed genes in high-grade squamous cervical intraepithelial lesions (Suman and Mishra, 2018). |
| |
| |
Entity | Colorectal cancer |
Note | Bonte et al. (Bonte et al., 2008) reported a high CDC7 expression in 8 of out 10 cases of colorectal cancer. In agreement, Chen et al. (Chen et al., 2013) reported a significantly higher CDC7 mRNA and protein expression in samples from 39 colorectal patients compared to their tumor-adjacent normal colorectal tissues. Analysis of 1800 colorectal carcinomas, by immunohistochemistry and tissue microarray, showed that CDC7 was highly expressed. Of note, CDC7 expression was significantly associated with TP53, suggesting that CDC7 may be a potential target in a subset of tumors with high TP53 expression (Melling et al., 2015). In contrast, loss of CDC7 expression was significantly associated with high tumor stage and grade, but was not related to nodal status. In multivariate survival analysis, strong CDC7 expression was an independent marker of improved patient survival (Melling et al., 2015). |
| |
| |
Entity | Esophageal squamous cell carcinoma |
Note | CDC7 is highly expressed in esophageal squamous cell carcinoma (ESCC) tissues, and that CDC7 knockdown inhibits cell proliferation, migration, and invasion, and induces apoptosis in ESCC cells. In addition, downregulation of CDC7 also partially enhances the chemosensitivity of ESCC cells to cisplatin and 5-fluorouracil, indicating that CDC7 may serve as a potential therapeutic target in ESCC (Cao and Lu, 2019). |
| |
| |
Entity | Glioblastoma |
Note | Inhibition of CDC7 by inhibitor PHA-767491 significantly reduced cell viability, proliferation, migration, invasion, and tumorigenesis, and induced apoptosis in glioblastoma models (Erbayraktar et al., 2016; Li et al., 2018). Li et al. (Li et al., 2018) identified that CDC7 expression was enhanced and functionally necessary for proliferation in glioblastomas, and its high expression was associated with poor prognosis. |
| |
| |
Entity | Head and neck squamous cell carcinoma |
Note | Human papillomavirus (HPV) is associated with a subset of head and neck squamous cell carcinoma (HNSCC) that can harbor HPV DNA and it was suggestive that there are biological and clinical differences between HPV positive (HPV +) and negative (HPV -) HNSCC. Slebos et al. (Slebos et al., 2006), comparing gene expression profiles of HPV+ and HPV- tumors, found 91 genes differentially expressed, including high CDC7 expression in HPV+ HNSCC. |
| |
| |
Entity | Hematological neoplasms |
Note | Hess and colleagues (Hess et al., 1998) identified the sequence of encoding human gene CDC7 and reported its overexpression in several types of cancers, including hematological neoplasms. Latterly, it was confirmed by Bont et al. (Bonte et al., 2008) in additional leukemia cellular models. In chronic lymphocytic leukemia (CLL), CDC7 was expressed and activated in lymph node biopsies. A similar finding was also observed in an in vitro model that partially recapitulates lymph node proliferation centers of CLL. These data suggested a potential role for CDC7 in the aberrant lymph node microenvironment (Natoni et al., 2011). In addition, high CDC7 expression was associated with poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL) (Hou et al., 2012b; Hou et al., 2011; Krawczyk et al., 2009). In DLBCL cell lines, CDC7 silencing combined with rituximab synergistically increased apoptosis (Hou et al., 2012a). The dual CDC7/ CDK9 inhibitor, PHA-767491, also induced cell death on a panel of multiple myeloma cell lines and primary patient samples alone or in combination with drugs currently used in the clinics, including the TP53 mutant cells that developed resistance to dexamethasone, melphalan, and doxorubicin. PHA-767491 had the same effect on primary myeloma cells from patients who relapsed with progressive refractory disease. These data suggested that the mechanisms leading to chemoresistance in myeloma may not affect the activity of a dual CDC7/CDK9 inhibitor, thus supporting further evaluation of CDC7 and CDK9 targeting in multiple myeloma (Natoni et al., 2013). In acute myeloid leukemia (AML), the dual CDC7/CDK9 inhibitor, PHA-767491, downregulated MCL1 and sensitized AML cell lines and primary AML blasts to BCL2 inhibitors, ABT-737 and ABT-199 (O' Reilly et al., 2018). |
| |
| |
Entity | Hepatocellular carcinoma |
Note | Using gene expression data sets, Zhuang et al. (Zhuang et al., 2018) detected that expression of various genes, including CDC7, was increased in hepatocellular carcinoma tissues compared to adjacent normal tissues. CDC7 overexpression was correlated with advanced histological grade and/or vascular invasion, and predicted worse overall and disease-free survival in hepatocellular carcinoma patients (Zhuang et al., 2018). It is important to highlight that the CDC7 inhibitor (PHA-767491) had a synergistic antitumor effect with 5-FU, exhibiting stronger cytotoxicity and inducing significant apoptosis in hepatocellular carcinoma cell lines and xenograft models (Li et al., 2015). |
| |
| |
Entity | Lung cancer |
Note | In non-small lung cancer (NSCLC) cell lines and tissue samples, CDC7 expression was highly expressed (Bonte et al., 2008). In agreement, CDC7 was significantly increased in lung adenocarcinoma tissues, as observed by immunohistochemistry and gene expression analysis in lung adenocarcinoma (Cao, 2019). In another study, high CDC7 expression significantly correlates with TP53 mutational status and predicts poor clinical outcomes in lung adenocarcinoma patients. In an experimental lung cancer model, CDC7 was also upregulated by gain-of-function mutant TP53, which induced cell cycle progression and tumorigenesis (Datta et al., 2017). |
| |
| |
Entity | Melanoma |
Note | CDC7 gene is located at chromosome 1p22 band, which was identified as a melanoma susceptibility locus with the high frequency of loss of heterozygosity (Walker et al., 2004). In a series of benign and dysplastic nevi, primary cutaneous melanomas and melanoma cutaneous metastasis samples, CDC7 regulatory subunits, DBF4, were found to be upregulated in malignant tissues (Nambiar et al., 2007), which was associated with shorter relapse-free survival. In the same study, DBF4 depletion reduced melanoma cell survival and proliferation (Nambiar et al., 2007). Clarke and colleagues (Clarke et al., 2009), using a tissue microarray containing 40 melanomas, 40 Spitz tumors, and 30 nevi reported that invasive melanomas and atypical Spitz nevi exhibited the highest CDC7 expression. In order to better understand the transcriptional regulation cell cycle checkpoints in melanocytes and melanoma cell lines, Kaufmann et al. (Kaufmann et al., 2008) analyzed global gene expression patterns upon DNA damage induced by ionizing radiation, and most melanoma cell lines (11 of out 16) showed significant defects in checkpoints, which included reduced expression of TP53 transcriptional targets, and enhanced expression of proliferation-associated genes. Of note, defective melanomas at checkpoint G1 exhibited higher levels of DNA synthesis-related genes, including CDC7 and CKS1B. Using a VSV-cDNA library and B16 melanoma tumors, CDC7 was identified (among others) as a potential immunogenic antigen for chemotherapy or immunotherapy (Zaidi et al., 2015). |
| |
| |
Entity | Oral squamous cell carcinoma |
Note | Evaluating CDC7 protein expression, by immunohistochemistry, in a cohort of 105 oral squamous cell carcinoma (OSCC) tumors and 30 benign oral tissues, CDC7 overexpression was found in 91% of tumor cases and 1% benign cases (Cheng et al., 2013). In multivariate analysis, CDC7 was an independent marker for overall survival in a cohort of 80 OSCC patients. In OSCC cell lines, overexpression of CDC7 inhibited genotoxin-induced apoptosis, suggesting that high CDC7 expression increases chemotherapy resistance (Cheng et al., 2013). Yong-Deok and colleagues (Yong-Deok et al., 2015) investigated the expression of inflammation-associated genes in samples from tumor and normal tissue from OSCC patients, in which genetic analysis of functional networks and ontologies identified CDC7 as one of the relevant genes. Pharmacological CDC7 inhibition with XL413 markedly reduced cell viability and proliferation by induction of apoptosis in OSCC cell lines (Jin et al., 2018). |
| |
| |
Entity | Osteosarcoma |
Note | In order to screen for key osteosarcoma biomarkers, Liu et al. (Liu et al., 2016) systematically screened mRNA and proteins differently expressed, and CDC7 was found as part of a gene signature for osteosarcoma. |
| |
| |
Entity | Ovarian carcinoma |
Note | CDC7 was a strong independent prognostic marker in epithelial ovarian carcinoma and CDC7 targeted inhibition leads to specific tumor cell death. In a cohort of 143 cases of ovarian cancer, increased levels of CDC7 protein were significantly associated with reduced tumor differentiation, advanced clinical stage, genomic instability, and accelerated cell cycle progression (Kulkarni et al., 2009). Moreover, CDC7 predicted disease-free survival, regardless of age, tumor grade and stage. CDC7 downregulation by siRNA in ovarian cancer cells (SKOV-3 and Caov-3) resulted in high levels of apoptosis (Kulkarni et al., 2009). |
| |
| |
Entity | Pancreatic cancer |
Note | In a cohort of 73 pancreatic adenocarcinoma patients, including 24 controls, CDC7 was highly expressed in pancreatic adenocarcinoma compared to benign pancreatic tissue, as observed by immunohistochemistry (Huggett et al., 2016). CDC7 depletion using siRNA and PHA-76749, a CDC7 small molecule inhibitor, in pancreatic cancer cellular models (Capan-1 and PANC-1), resulted in marked apoptotic cell death. Using human pancreatic cell lines (Capan-1, BxPC3, and PANC-1), the preclinical efficacy of another CDC7 inhibitor, MSK-777, was reported (induction of cell cycle arrest in G1/S and apoptosis) (Skoura et al., 2013). Taken together, these results indicated that CDC7 is a potential target and may be used as a complementary diagnosis marker to predict responses in pancreatic adenocarcinoma. |
| |
| |
Entity | Papillary thyroid carcinoma |
Note | Fluge et al. (Fluge et al., 2006) studied gene expression profile using cDNA microarray in papillary thyroid carcinoma samples, including 7 clinically aggressive carcinomas, 10 differentiated thyroid papillary carcinomas, and normal thyroid tissues, which were confirmed by RT-PCR, in situ hybridization and immunohistochemistry. Patients with aggressive and poorly differentiated thyroid carcinoma were specifically characterized by the marked positive regulation of several genes related to cell proliferation, including CDC7 (Fluge et al., 2006). |
| |
| |
Entity | Salivary gland tumor |
Note | Jaafari-Ashkavandi et al. (Jaafari-Ashkavandi et al., 2019) reported high CDC7 expression in malignant salivary gland tumors compared to pleomorphic adenomas, and its positive correlation with tumor differentiation in samples from 15 cystic adenoid carcinomas, 12 mucoepidermoid carcinomas, 14 pleomorphic adenomas, and 5 normal salivary glands (total 46 patients and donors). |
| |
| |
Entity | Uterine leiomyosarcoma |
Note | Barlin and colleagues (Barlin et al., 2015) compared the molecular profiles of 23 samples of uterine leiomyosarcoma (ULMS) and 29 samples of normal myometrium (NL) to identify clinically relevant molecular subtypes. Pathway analyses of genes differentially expressed between ULMS and NL samples identified over-representation of cell cycle regulation, DNA repair, and genomic integrity. External validation confirmed differential expression in 31 genes, with 84% overexpressed genes, including CDC7 and other cell cycle regulators (Barlin et al., 2015). |
| |
Hsk1-Dfp1 is required for heterochromatin-mediated cohesion at centromeres |
Bailis JM, Bernard P, Antonelli R, Allshire RC, Forsburg SL |
Nat Cell Biol 2003 Dec;5(12):1111-6 |
PMID 14625560 |
|
Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcome |
Barlin JN, Zhou QC, Leitao MM, Bisogna M, Olvera N, Shih KK, Jacobsen A, Schultz N, Tap WD, Hensley ML, Schwartz GK, Boyd J, Qin LX, Levine DA |
Neoplasia 2015 Feb;17(2):183-9 |
PMID 25748237 |
|
Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation |
Bonte D, Lindvall C, Liu H, Dykema K, Furge K, Weinreich M |
Neoplasia 2008 Sep;10(9):920-31 |
PMID 18714392 |
|
The Cdc7 protein kinase is required for origin firing during S phase |
Bousset K, Diffley JF |
Genes Dev 1998 Feb 15;12(4):480-90 |
PMID 9472017 |
|
miR888 regulates cancer progression by targeting multiple targets in lung adenocarcinoma |
Cao JX |
Oncol Rep 2019 Jun;41(6):3367-3376 |
PMID 31002360 |
|
Targeting CDC7 improves sensitivity to chemotherapy of esophageal squamous cell carcinoma |
Cao JX, Lu Y |
Onco Targets Ther 2018 Dec 20;12:63-74 |
PMID 30588031 |
|
Expression of huCdc7 in colorectal cancer |
Chen HJ, Zhu Z, Wang XL, Feng QL, Wu Q, Xu ZP, Wu J, Yu XF, Qian HL, Lu Q |
World J Gastroenterol 2013 May 28;19(20):3130-3 |
PMID 23716994 |
|
Increased Cdc7 expression is a marker of oral squamous cell carcinoma and overexpression of Cdc7 contributes to the resistance to DNA-damaging agents |
Cheng AN, Jiang SS, Fan CC, Lo YK, Kuo CY, Chen CH, Liu YL, Lee CC, Chen WS, Huang TS, Wang TY, Lee AY |
Cancer Lett 2013 Sep 1;337(2):218-25 |
PMID 23684929 |
|
Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer |
Choschzick M, Lebeau A, Marx AH, Tharun L, Terracciano L, Heilenkötter U, Jaenicke F, Bokemeyer C, Simon R, Sauter G, Schwarz J |
Hum Pathol 2010 Mar;41(3):358-65 |
PMID 19896697 |
|
Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi |
Clarke LE, Fountaine TJ, Hennessy J, Bruggeman RD, Clarke JT, Mauger DT, Helm KF |
J Cutan Pathol 2009 Apr;36(4):433-8 |
PMID 19278428 |
|
An ATR- and Cdc7-dependent DNA damage checkpoint that inhibits initiation of DNA replication |
Costanzo V, Shechter D, Lupardus PJ, Cimprich KA, Gottesman M, Gautier J |
Mol Cell 2003 Jan;11(1):203-13 |
PMID 12535533 |
|
p53 gain-of-function mutations increase Cdc7-dependent replication initiation |
Datta A, Ghatak D, Das S, Banerjee T, Paul A, Butti R, Gorain M, Ghuwalewala S, Roychowdhury A, Alam SK, Das P, Chatterjee R, Dasgupta M, Panda CK, Kundu GC, Roychoudhury S |
EMBO Rep 2017 Nov;18(11):2030-2050 |
PMID 28887320 |
|
Cell division cycle 7-kinase inhibitor PHA-767491 hydrochloride suppresses glioblastoma growth and invasiveness |
Erbayraktar Z, Alural B, Erbayraktar RS, Erkan EP |
Cancer Cell Int 2016 Nov 18;16:88 |
PMID 27891063 |
|
Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships |
Ermoli A, Bargiotti A, Brasca MG, Ciavolella A, Colombo N, Fachin G, Isacchi A, Menichincheri M, Molinari A, Montagnoli A, Pillan A, Rainoldi S, Sirtori FR, Sola F, Thieffine S, Tibolla M, Valsasina B, Volpi D, Santocanale C, Vanotti E |
J Med Chem 2009 Jul 23;52(14):4380-90 |
PMID 19555113 |
|
Gene expression in poorly differentiated papillary thyroid carcinomas |
Fluge Ø, Bruland O, Akslen LA, Lillehaug JR, Varhaug JE |
Thyroid 2006 Feb;16(2):161-75 |
PMID 16676402 |
|
Kinase Gene Expression Profiling of Metastatic Clear Cell Renal Cell Carcinoma Tissue Identifies Potential New Therapeutic Targets |
Ghatalia P, Yang ES, Lasseigne BN, Ramaker RC, Cooper SJ, Chen D, Sudarshan S, Wei S, Guru AS, Zhao A, Cooper T, Della Manna DL, Naik G, Myers RM, Sonpavde G |
PLoS One 2016 Aug 30;11(8):e0160924 |
PMID 27574806 |
|
Patterns of somatic mutation in human cancer genomes |
Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Brasseur F, Looijenga L, Weber BL, Chiew YE, DeFazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF, Chenevix-Trench G, Tan MH, Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal PA, Stratton MR |
Nature 2007 Mar 8;446(7132):153-8 |
PMID 17344846 |
|
A human homolog of the yeast CDC7 gene is overexpressed in some tumors and transformed cell lines |
Hess GF, Drong RF, Weiland KL, Slightom JL, Sclafani RA, Hollingsworth RE |
Gene 1998 Apr 28;211(1):133-40 |
PMID 9573348 |
|
Effects of CDC7 gene silencing and Rituximab on apoptosis in diffuse large B cell lymphoma cells |
Hou Y, Wang HQ, Ba Y |
J Cancer Res Clin Oncol 2012 Dec;138(12):2027-34 |
PMID 22806309 |
|
Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint |
Huggett MT, Tudzarova S, Proctor I, Loddo M, Keane MG, Stoeber K, Williams GH, Pereira SP |
Oncotarget 2016 Apr 5;7(14):18495-507 |
PMID 26921250 |
|
Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor |
Iwai K, Nambu T, Dairiki R, Ohori M, Yu J, Burke K, Gotou M, Yamamoto Y, Ebara S, Shibata S, Hibino R, Nishizawa S, Miyazaki T, Homma M, Oguro Y, Imada T, Cho N, Uchiyama N, Kogame A, Takeuchi T, Kurasawa O, Yamanaka K, Niu H, Ohashi A |
Sci Adv 2019 May 22;5(5):eaav3660 |
PMID 31131319 |
|
Overexpression of CDC7 in malignant salivary gland tumors correlates with tumor differentiation |
Jaafari-Ashkavandi Z, Ashraf MJ, Abbaspoorfard AA |
Braz J Otorhinolaryngol 2019 Mar - Apr;85(2):144-149 |
PMID 29339028 |
|
Cell division cycle 7 is a potential therapeutic target in oral squamous cell carcinoma and is regulated by E2F1 |
Jin S, Ma H, Yang W, Ju H, Wang L, Zhang Z |
J Mol Med (Berl) 2018 Jun;96(6):513-525 |
PMID 29713760 |
|
Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression |
Kaufmann WK, Nevis KR, Qu P, Ibrahim JG, Zhou T, Zhou Y, Simpson DA, Helms-Deaton J, Cordeiro-Stone M, Moore DT, Thomas NE, Hao H, Liu Z, Shields JM, Scott GA, Sharpless NE |
J Invest Dermatol 2008 Jan;128(1):175-87 |
PMID 17597816 |
|
Cdc7 kinase mediates Claspin phosphorylation in DNA replication checkpoint |
Kim JM, Kakusho N, Yamada M, Kanoh Y, Takemoto N, Masai H |
Oncogene 2008 May 29;27(24):3475-82 |
PMID 18084324 |
|
Inactivation of Cdc7 kinase in mouse ES cells results in S-phase arrest and p53-dependent cell death |
Kim JM, Nakao K, Nakamura K, Saito I, Katsuki M, Arai K, Masai H |
EMBO J 2002 May 1;21(9):2168-79 |
PMID 11980714 |
|
Hypomorphic mutation in an essential cell-cycle kinase causes growth retardation and impaired spermatogenesis |
Kim JM, Takemoto N, Arai K, Masai H |
EMBO J 2003 Oct 1;22(19):5260-72 |
PMID 14517263 |
|
Functions of mammalian Cdc7 kinase in initiation/monitoring of DNA replication and development |
Kim JM, Yamada M, Masai H |
Mutat Res 2003 Nov 27;532(1-2):29-40 |
PMID 14643427 |
|
Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines |
Kim SH, Ho JN, Jin H, Lee SC, Lee SE, Hong SK, Lee JW, Lee ES, Byun SS |
Investig Clin Urol 2016 Jan;57(1):63-72 |
PMID 26966728 |
|
Discovery of XL413, a potent and selective CDC7 inhibitor |
Koltun ES, Tsuhako AL, Brown DS, Aay N, Arcalas A, Chan V, Du H, Engst S, Ferguson K, Franzini M, Galan A, Holst CR, Huang P, Kane B, Kim MH, Li J, Markby D, Mohan M, Noson K, Plonowski A, Richards SJ, Robertson S, Shaw K, Stott G, Stout TJ, Young J, Yu P, Zaharia CA, Zhang W, Zhou P, Nuss JM, Xu W, Kearney PC |
Bioorg Med Chem Lett 2012 Jun 1;22(11):3727-31 |
PMID 22560567 |
|
Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma |
Kulkarni AA, Kingsbury SR, Tudzarova S, Hong HK, Loddo M, Rashid M, Rodriguez-Acebes S, Prevost AT, Ledermann JA, Stoeber K, Williams GH |
Clin Cancer Res 2009 Apr 1;15(7):2417-25 |
PMID 19318489 |
|
Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-d]pyrimidinone-Based Cdc7 Inhibitor with a Quinuclidine Moiety (TAK-931) as an Orally Active Investigational Antitumor Agent |
Kurasawa O, Miyazaki T, Homma M, Oguro Y, Imada T, Uchiyama N, Iwai K, Yamamoto Y, Ohori M, Hara H, Sugimoto H, Iwata K, Skene R, Hoffman I, Ohashi A, Nomura T, Cho N |
J Med Chem 2020 Feb 13;63(3):1084-1104 |
PMID 31895562 |
|
How do Cdc7 and cyclin-dependent kinases trigger the initiation of chromosome replication in eukaryotic cells? Genes Dev |
Labib K |
2010 Jun 15;24(12):1208-19 doi: 10 |
PMID 20551170 |
|
Dbf4 is direct downstream target of ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR) protein to regulate intra-S-phase checkpoint |
Lee AY, Chiba T, Truong LN, Cheng AN, Do J, Cho MJ, Chen L, Wu X |
J Biol Chem 2012 Jan 20;287(4):2531-43 |
PMID 22123827 |
|
CDC7-dependent transcriptional regulation of RAD54L is essential for tumorigenicity and radio-resistance of glioblastoma |
Li Q, Xie W, Wang N, Li C, Wang M |
Transl Oncol 2018 Apr;11(2):300-306 |
PMID 29413763 |
|
Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil |
Li W, Zhao XL, Shang SQ, Shen HQ, Chen X |
Curr Cancer Drug Targets 2015;15(3):196-204 |
PMID 25643258 |
|
Identification of key biomarkers involved in osteosarcoma using altered modules |
Liu ZZ, Cui ST, Tang B, Wang ZZ, Luan ZX |
Genet Mol Res 2016 Aug 26;15(3) |
PMID 27706618 |
|
Dbf4-dependent CDC7 kinase links DNA replication to the segregation of homologous chromosomes in meiosis I |
Matos J, Lipp JJ, Bogdanova A, Guillot S, Okaz E, Junqueira M, Shevchenko A, Zachariae W |
Cell 2008 Nov 14;135(4):662-78 |
PMID 19013276 |
|
Regulation of chromosome dynamics by Hsk1/Cdc7 kinase |
Matsumoto S, Masai H |
Biochem Soc Trans 2013 Dec;41(6):1712-9 |
PMID 24256280 |
|
A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy |
McLaughlin RP, He J, van der Noord VE, Redel J, Foekens JA, Martens JWM, Smid M, Zhang Y, van de Water B |
Breast Cancer Res 2019 Jul 1;21(1):77 |
PMID 31262335 |
|
Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancer |
Melling N, Muth J, Simon R, Bokemeyer C, Terracciano L, Sauter G, Izbicki JR, Marx AH |
Diagn Pathol 2015 Jul 25;10:125 |
PMID 26208856 |
|
First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents |
Menichincheri M, Bargiotti A, Berthelsen J, Bertrand JA, Bossi R, Ciavolella A, Cirla A, Cristiani C, Croci V, D'Alessio R, Fasolini M, Fiorentini F, Forte B, Isacchi A, Martina K, Molinari A, Montagnoli A, Orsini P, Orzi F, Pesenti E, Pezzetta D, Pillan A, Poggesi I, Roletto F, Scolaro A, Tatò M, Tibolla M, Valsasina B, Varasi M, Volpi D, Santocanale C, Vanotti E |
2 Lead discovery |
PMID 19115845 |
|
Identification and functional characterization of ASK/Dbf4, a novel cell survival gene in cutaneous melanoma with prognostic relevance |
Nambiar S, Mirmohammadsadegh A, Hassan M, Mota R, Marini A, Alaoui A, Tannapfel A, Hegemann JH, Hengge UR |
Carcinogenesis 2007 Dec;28(12):2501-10 |
PMID 17768177 |
|
Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models |
Natoni A, Coyne MR, Jacobsen A, Rainey MD, O'Brien G, Healy S, Montagnoli A, Moll J, O'Dwyer M, Santocanale C |
Cancers (Basel) 2013 Jul 24;5(3):901-18 |
PMID 24202326 |
|
Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells |
Natoni A, Murillo LS, Kliszczak AE, Catherwood MA, Montagnoli A, Samali A, O'Dwyer M, Santocanale C |
Mol Cancer Ther 2011 Sep;10(9):1624-34 |
PMID 21768328 |
|
Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML |
O' Reilly E, Dhami SPS, Baev DV, Ortutay C, Halpin-McCormick A, Morrell R, Santocanale C, Samali A, Quinn J, O'Dwyer ME, Szegezdi E |
Sci Rep 2018 Oct 25;8(1):15752 |
PMID 30361682 |
|
Cdc7-dependent and -independent phosphorylation of Claspin in the induction of the DNA replication checkpoint |
Rainey MD, Harhen B, Wang GN, Murphy PV, Santocanale C |
Cell Cycle 2013 May 15;12(10):1560-8 |
PMID 23598722 |
|
Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers |
Rodriguez-Acebes S, Proctor I, Loddo M, Wollenschlaeger A, Rashid M, Falzon M, Prevost AT, Sainsbury R, Stoeber K, Williams GH |
Am J Pathol 2010 Oct;177(4):2034-45 |
PMID 20724597 |
|
Drug design with Cdc7 kinase: a potential novel cancer therapy target |
Sawa M, Masai H |
Drug Des Devel Ther 2009 Feb 6;2:255-64 |
PMID 19920912 |
|
O Cdc7 kinase where art thou? Curr Genet |
Sclafani RA, Hesselberth JR |
2018 Jun;64(3):677-680 doi: 10 |
PMID 29134273 |
|
Preclinical research in treatment of pancreatic cancer |
Skoura E, Syrigos KN, Saif MW |
JOP 2013 Jul 10;14(4):384-7 |
PMID 23846933 |
|
Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma |
Slebos RJ, Yi Y, Ely K, Carter J, Evjen A, Zhang X, Shyr Y, Murphy BM, Cmelak AJ, Burkey BB, Netterville JL, Levy S, Yarbrough WG, Chung CH |
Clin Cancer Res 2006 Feb 1;12(3 Pt 1):701-9 |
PMID 16467079 |
|
Over expression of DNA damage and cell cycle dependent proteins are associated with poor survival in patients with adrenocortical carcinoma |
Subramanian C, Cohen MS |
Surgery 2019 Jan;165(1):202-210 |
PMID 30413320 |
|
An interaction network driven approach for identifying biomarkers for progressing cervical intraepithelial neoplasia |
Suman S, Mishra A |
Sci Rep 2018 Aug 27;8(1):12927 |
PMID 30150654 |
|
Cdc7-Drf1 kinase links chromosome cohesion to the initiation of DNA replication in Xenopus egg extracts |
Takahashi TS, Basu A, Bermudez V, Hurwitz J, Walter JC |
Genes Dev 2008 Jul 15;22(14):1894-905 |
PMID 18628396 |
|
Cdc7 is an active kinase in human cancer cells undergoing replication stress |
Tenca P, Brotherton D, Montagnoli A, Rainoldi S, Albanese C, Santocanale C |
J Biol Chem 2007 Jan 5;282(1):208-15 |
PMID 17062569 |
|
The role of Dbf4/Drf1-dependent kinase Cdc7 in DNA-damage checkpoint control |
Tsuji T, Lau E, Chiang GG, Jiang W |
Mol Cell 2008 Dec 26;32(6):862-9 |
PMID 19111665 |
|
Deletion mapping suggests that the 1p22 melanoma susceptibility gene is a tumor suppressor localized to a 9-Mb interval |
Walker GJ, Indsto JO, Sood R, Faruque MU, Hu P, Pollock PM, Duray P, Holland EA, Brown K, Kefford RF, Trent JM, Mann GJ, Hayward NK |
Genes Chromosomes Cancer 2004 Sep;41(1):56-64 |
PMID 15236317 |
|
ATR-Chk1-APC/CCdh1-dependent stabilization of Cdc7-ASK (Dbf4) kinase is required for DNA lesion bypass under replication stress |
Yamada M, Watanabe K, Mistrik M, Vesela E, Protivankova I, Mailand N, Lee M, Masai H, Lukas J, Bartek J |
Genes Dev 2013 Nov 15;27(22):2459-72 |
PMID 24240236 |
|
Molecular genetic study of novel biomarkers for early diagnosis of oral squamous cell carcinoma |
Yong-Deok K, Eun-Hyoung J, Yeon-Sun K, Kang-Mi P, Jin-Yong L, Sung-Hwan C, Tae-Yun K, Tae-Sung P, Soung-Min K, Myung-Jin K, Jong-Ho L |
Med Oral Patol Oral Cir Bucal 2015 Mar 1;20(2):e167-79 |
PMID 25475780 |
|
Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents |
Zaidi S, Blanchard M, Shim K, Ilett E, Rajani K, Parrish C, Boisgerault N, Kottke T, Thompson J, Celis E, Pulido J, Selby P, Pandha H, Melcher A, Harrington K, Vile R |
Mol Ther 2015 May;23(5):845-856 |
PMID 25544599 |
|
Upregulation of BUB1B, CCNB1, CDC7, CDC20, and MCM3 in Tumor Tissues Predicted Worse Overall Survival and Disease-Free Survival in Hepatocellular Carcinoma Patients |
Zhuang L, Yang Z, Meng Z |
Biomed Res Int 2018 Sep 30;2018:7897346 |
PMID 30363964 |
|
Serum Proteomic Signatures of Male Breast Cancer |
Zografos E, Anagnostopoulos AK, Papadopoulou A, Legaki E, Zagouri F, Marinos E, Tsangaris GT, Gazouli M |
Cancer Genomics Proteomics 2019 Mar-Apr;16(2):129-137 |
PMID 30850364 |
|